TRELLIS BIOSCIENCE, INC.
CF-404, a mixture of three native human monoclonal antibodies delivered by inhalation for pan-influenza treatment
- Sector
- Biotech
- Headquarters
- Menlo Park, CA
- Founded
- 2010
- Latest Form D
- $985K, Oct 2026
- Total capital
- $36.6M
- Federal grants
- $18.9M
- 17 awards · 2015–2022
- Rank in peer group#10 of 514
- Private capital raised
- $17.8M
- 7 Form D · last Oct 2026
- 0 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 15 pending · first 2025
- Rank in peer group#142 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 7th filing$985K
- Private capital raisedForm D · SEC · 6th filing$1.4M
- Private capital raisedForm D · SEC · 5th filing$4.1M
- Private capital raisedForm D · SEC · 4th filing$22.9M
- Private capital raisedForm D · SEC · 3rd filing$6.1M
- Federal grantHealth and Human S · Phase II · Biofilm disrupting antibody to treat respiratory and musculoskeletal infections$989K
- Federal grantHealth and Human S · Phase II · Strain-Independent Therapeutic Antibodies for Influenza$1.0M
- Private capital raisedForm D · SEC · 2nd filing$235K
- Private capital raisedForm D · SEC · 1st filing$11.5M
Show 15 earlier federal awards
- Federal grantHealth and Human S · Phase II · Biofilm disrupting antibody to treat respiratory and musculoskeletal infections$991K
- Federal grantHealth and Human S · Phase II · Strain-Independent Therapeutic Antibodies for Influenza$999K
- Federal grantHealth and Human S · Phase II · Therapeutic Antibody for RSV IIB$998K
- Federal grantHealth and Human S · Phase II · Biofilm disrupting antibody to treat respiratory and musculoskeletal infections$999K
- Federal grantHealth and Human S · Phase II · Strain-Independent Therapeutic Antibodies for Influenza$3M
- Federal grantHealth and Human S · Phase II · Therapeutic Antibody for RSV IIB$1M
- Federal grantHealth and Human S · Phase II · Therapeutic Antibody for RSV IIB$1M
- Federal grantHealth and Human S · Phase II · Strain-Independent Therapeutic Antibodies for Influenza$981K
- Federal grantHealth and Human S · Phase II · Therapeutic antibody for RSV$1.5M
- Federal grantHealth and Human S · Phase II · Therapeutic Antibodies for Biofilm Infections$1.0M
- Federal grantHealth and Human S · Phase II · Strain-Independent Therapeutic Antibodies for Influenza$987K
- Federal grantHealth and Human S · Phase II · Therapeutic antibody for RSV$1.3M
- Federal grantHealth and Human S · Phase I · Therapeutic Antibodies for Biofilm Infections$225K
- Federal grantHealth and Human S · Phase II · Strain-Independent Therapeutic Antibodies for Influenza$942K
- Federal grantHealth and Human S · Phase II · Therapeutic Antibodies for CMV$991K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#10 · top 2%
- Granted patents#142 · top 28%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Lawrence M. KauvarResearcherExecutive Officer, DirectorLinked by 1 patent · $4.2M in grants as PI
- Elisabeth WhitneyExecutive OfficerNamed in SEC Form D filings
- Geoff DillonExecutive OfficerNamed in SEC Form D filings
- Gerald McMahonDirectorNamed in SEC Form D filings
- James BroderickDirectorNamed in SEC Form D filings
- John FriedmanDirectorNamed in SEC Form D filings
Show all 13 people
- Larry KauvarExecutive OfficerNamed in SEC Form D filings
- Markus GoebelDirectorNamed in SEC Form D filings
- Nora MendeExecutive OfficerNamed in SEC Form D filings
- Somu SubramaniamDirectorNamed in SEC Form D filings
- Stefan RyserExecutive OfficerNamed in SEC Form D filings
- Stote EllsworthExecutive Officer, DirectorNamed in SEC Form D filings
- Thomas LavinDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 17- GrantedTherapeutic Protein Formulations Comprising Anti-dnabii Antibodies And Uses ThereofUSPTOUS 12,643,941
- GrantedAntibodies Useful In Passive Influenza Immunization, And Compositions, Combinations And Methods For Use ThereofUSPTOUS 12,491,245
- PendingRsv Passive And Active VaccinesUSPTOApplication 19028538
Show all 17 patent records
- Therapeutic Protein Formulations Comprising Anti-dnabii Antibodies And Uses ThereofJun 2, 2026 · US 12,643,941Granted
- Antibodies Useful In Passive Influenza Immunization, And Compositions, Combinations And Methods For Use ThereofDec 9, 2025 · US 12,491,245Granted
- Rsv Passive And Active VaccinesJun 19, 2025 · Application 19028538Pending
- Anti-alk Antibodies And Uses ThereofAug 1, 2024 · Application 18545533Pending
- Diagnostics for Emerging DiseaseApr 25, 2024 · Application 18383777Pending
- Therapeutic Protein Formulations Comprising Anti-DNABII Antibodies and Uses ThereofApplication 63132252Pending
- Antibodies Useful In Passive Influenza ImmuizationApplication PCTUS2011040982Pending
- High Affinity Human Antibodies To Human Cytomegalovirus (cmv) Gb ProteinApplication PCTUS2011040761Pending
- Improved Antibodies Immunoreactive With Heregulin-coupled HER3Application PCTUS2010033058Pending
- Anti-rsv G Protein AntibodiesApplication PCTUS2008081175Pending
- Cellport Tm ApplicationsApplication PCTUS2007073293Pending
- Homogeneous Competition AssaysApplication PCTUS2004040480Pending
- Translocation TaggingApplication PCTUS2004024946Pending
- Anti-alk Antibodies & Uses ThereofApplication PCTUS2022035151Pending
- Therapeutic Protein Formulations Comprising Anti-dnabii Antibodies And Uses ThereofApplication PCTUS2021065542Pending
- Therapeutic Protein Formulations Comprising Anti-dnabii Antibodies And Uses ThereofApplication 63275246Pending
- Native Human Anti-alk AntibodiesApplication 63215947Pending
Related companies, and why
- Jaguar Gene TherapySimilar federal contract value in Biotech · null in contracts
- Versa Integrated Solutions, Inc.Similar federal contract value in Biotech · null in contracts
- XYLYX BIO, INC.Similar federal contract value in Biotech · null in contracts
- ALLIANCE DISCOVERY, INC.Similar federal contract value in Biotech · null in contracts
- RIDGELINE THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
- COMPOVAX, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .